ETR:MOR - MorphoSys Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started €97.00 -2.30 (-2.32 %) (As of 12/14/2018 04:00 PM ET)Previous Close€97.00Today's Range€96.15 - €98.3052-Week Range€49.63 - €88.10Volume108,901 shsAverage Volume153,687 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartHeadlines Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation. Its product pipeline includes MOR208, a humanized monoclonal antibody that targets the antigen CD19, which is in Phase III clinical trial for the treatment of B cell malignancies; and MOR202, a human monoclonal HuCAL antibody directed against CD38, which is in Phase II trial for the treatment of multiple myeloma and other cancers. The company's product pipeline also comprises MOR103/GSK3196165, a human HuCAL antibody directed against granulocyte-macrophage colony-stimulating factor that is in Phase II clinical trial for treating rheumatoid arthritis and inflammatory hand osteoarthritis. In addition, its product pipeline includes MOR106, a human monoclonal antibody directed against IL-17C, which is in Phase I clinical trial for the treatment of atopic dermatitis; and MOR107 that is in preclinical investigation with a focus on oncology indications. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macao; and a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs. The company was founded in 1992 and is headquartered in Planegg, Germany. Receive MOR News and Ratings via Email Sign-up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange ETR Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolETR:MOR Previous Symbol CUSIPN/A Webwww.morphosys.de Phone+49-89-899270 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees322 Outstanding SharesN/AMarket Cap$0.00 OptionableNot Optionable MorphoSys (ETR:MOR) Frequently Asked Questions What is MorphoSys' stock symbol? MorphoSys trades on the ETR under the ticker symbol "MOR." What price target have analysts set for MOR? 10 equities research analysts have issued 1 year price targets for MorphoSys' stock. Their predictions range from €56.00 to €130.00. On average, they anticipate MorphoSys' share price to reach €98.30 in the next twelve months. This suggests a possible upside of 1.3% from the stock's current price. View Analyst Price Targets for MorphoSys. What is the consensus analysts' recommendation for MorphoSys? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MorphoSys in the last year. There are currently 2 sell ratings, 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for MorphoSys. Has MorphoSys been receiving favorable news coverage? Headlines about MOR stock have trended somewhat negative recently, according to InfoTrie. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. MorphoSys earned a coverage optimism score of -1.1 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 8.0 out of 10, indicating that recent media coverage is very likely to have an impact on the stock's share price in the next several days. Who are some of MorphoSys' key competitors? Some companies that are related to MorphoSys include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE), Ampliphi Biosciences (APHB) and Antibe Therapeutics (ATE). Who are MorphoSys' key executives? MorphoSys' management team includes the folowing people: Dr. Simon E. Moroney, Chairman of Management Board & CEO (Age 59)Mr. Jens H. Holstein, CFO & Member of Management Board (Age 54)Dr. Markus Enzelberger, Chief Scientific Officer & Member of Management Board (Age 48)Dr. Malte Peters, Chief Devel. Officer & Member of Management Board (Age 56)Dr. Marlies Sproll, Special Adviser to the Chief Exec. Officer (Age 60) What is MorphoSys' stock price today? One share of MOR stock can currently be purchased for approximately €97.00. What is MorphoSys' official website? The official website for MorphoSys is https://www.morphosys.de/. How can I contact MorphoSys? MorphoSys' mailing address is Semmelweisstr. 7, PLANEGG, 82152, Germany. The company can be reached via phone at +49-89-899270. MarketBeat Community Rating for MorphoSys (ETR MOR)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 215 (Vote Outperform)Underperform Votes: 157 (Vote Underperform)Total Votes: 372MarketBeat's community ratings are surveys of what our community members think about MorphoSys and other stocks. Vote "Outperform" if you believe MOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MOR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/15/2018 by MarketBeat.com StaffFeatured Article: What is Cost of Capital?